0000899243-15-005097.txt : 20150921
0000899243-15-005097.hdr.sgml : 20150921
20150921170030
ACCESSION NUMBER: 0000899243-15-005097
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150918
FILED AS OF DATE: 20150921
DATE AS OF CHANGE: 20150921
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ARCA biopharma, Inc.
CENTRAL INDEX KEY: 0000907654
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 363855489
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11080 CIRCLEPOINT ROAD
STREET 2: SUITE 140
CITY: WESTMINSTER
STATE: CO
ZIP: 80020
BUSINESS PHONE: 720-940-2200
MAIL ADDRESS:
STREET 1: 11080 CIRCLEPOINT ROAD
STREET 2: SUITE 140
CITY: WESTMINSTER
STATE: CO
ZIP: 80020
FORMER COMPANY:
FORMER CONFORMED NAME: NUVELO INC
DATE OF NAME CHANGE: 20030203
FORMER COMPANY:
FORMER CONFORMED NAME: HYSEQ INC
DATE OF NAME CHANGE: 19970610
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BRISTOW MICHAEL R
CENTRAL INDEX KEY: 0001266125
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-22873
FILM NUMBER: 151117868
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-09-18
0
0000907654
ARCA biopharma, Inc.
ABIO
0001266125
BRISTOW MICHAEL R
ARCA BIOPHARMA, INC.
11080 CIRCLEPOINT ROAD, SUITE 140
WESTMINSTER
CO
80020
1
1
0
0
See Remarks
Common Stock
2015-09-18
4
S
0
1809
6.33
D
46086
D
Common Stock
19986
I
By Investocor Trust as sole Trustee
Common Stock
25459
I
By NFS Custodian for Michael Bristow's IRA
Represents shares of common stock sold pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person for satisfaction of their tax withholding obligation with respect to the vesting of previously reported Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's 2013 Equity Incentive Plan (the "Plan").
Includes (i) remaining 5,952 previously reported shares issued as RSUs under the Plan that vests on 9/17/16, (ii) 6,075 previously reported shares issued as RSUs under the Plan that vest in three equal annual installments beginning on 2/27/16, and (iii) 6,871 previously reported shares issued as RSUs under the Plan that vest in three equal annual installments beginning April 2, 2016, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined under the Plan; and 27,188 previously reported shares of common stock held directly.
The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $6.33 to $6.35. Upon request of the SEC staff, ARCA biopharma, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
Includes 118 shares that were inadvertently omitted from the prior filing.
President and Chief Executive Officer
/s/ Brian L. Selby, Attorney-in-Fact
2015-09-21